Search Results for “HIV” – Page 4 – media

U.S. Food and Drug Administration Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection

Gilead Sciences, Inc.(NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Biktarvy® (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF), a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection. Biktarvy combines the novel, unboosted integrase strand transfer inhibitor (INSTI) bictegravir, with the demonstrated safety and efficacy profile of the Descovy® (FTC/TAF) dual nucleoside reverse transcriptase inhibitor (NRTI) backbone, and is the smallest INSTI-based triple-therapy STR available.
- Source: gilead
- 906
- February 26, 2018
Biktarvy FDA Gilead Sciences HIV-1 infection
ViiV kicks off PhIII trial of two-drug HIV regimen

ViiV Healthcare, an HIV specialist firm majority owned by GlaxoSmithKline, has announced the launch of a late-stage study investigating the effectiveness of a two-drug regimen programme in patients with HIV.
- Source: pharmatimes
- 571
- February 12, 2018
Clinical Trial HIV Phase TANGO
Roche introduces new sample collection device for HIV plasma viral load testing

The new card solution helps to simplify blood collection and sample transportation through providing a small amount of a patient’s blood from a fingertip.
- Source: MDBR
- 507
- January 9, 2018
Company Insight HIV Roche
J&J-led coalition launches a landmark efficacy study for an HIV mosaic vaccine

For decades now, investigators have been drawn to HIV vaccine research — a Holy Grail in anti-viral research that would have an enormous impact in a world that still sees two million new infections every year.
- Source: Endpts;
- 519
- December 4, 2017
HIV Market Views vaccine virus
Combination HIV prevention reduces new infections by 42 percent in Ugandan district

A study published today in the New England Journal of Medicine provides real-world evidence that implementing a combination of proven HIV prevention measures across communities can substantially reduce new HIV infections in a population.
- Source: medicalxpress
- 513
- November 30, 2017
ART HIV NIH Researches
FDA approves first two-drug regimen for certain patients with HIV

The U.S. Food and Drug Administration(FDA) today approved Juluca, the first complete treatment regimen containing only two drugs to treat certain adults with human immunodeficiency virus type 1 (HIV-1) instead of three or more drugs included in standard HIV treatment.
- Source: finance.yahoo
- 479
- November 22, 2017
FDA HIV immunodeficiency Juluca New Approvals
UNAIDS announces nearly 21 million people living with HIV now on treatment

Remarkable progress is being made on HIV treatment. Ahead of World AIDS Day, UNAIDS has launched a new report showing that access to treatment has risen significantly. In 2000, just 685 000 people living with HIV had access to antiretroviral therapy. By June 2017, around 20.9 million people had access to the life-saving medicines. Such a dramatic scale-up could not have happened without the courage and determination of people living with HIV demanding and claiming their rights, backed up by steady, strong leadership and financial commitment.
- Source: reliefweb
- 447
- November 21, 2017
antiretroviral HIV UNAIDS
New tool developed to study stem cell transplants as a potential way to treat HIV

A decade ago, the medical world was shocked when a patient in Berlin, Germany, had been declared free of HIV after receiving a stem cell transplant to treat cancer. Doctors have repeatedly tried to replicate the result, but this HIV cure has evaded other patients so far.
- Source: sciencedaily
- 495
- November 14, 2017
HIV Market Views stem cells
Durable end to the HIV/AIDS pandemic likely will require an HIV vaccine

Despite remarkable gains in the treatment and prevention of HIV infection, development of an effective HIV vaccine likely will be necessary to achieve a durable end to the HIV/AIDS pandemic, according to a new commentary from Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
- Source: Sciencedaily
- 563
- October 13, 2017
AIDS HIV Researches vaccine
Pfizer unloads Colorado plant as it continues to hive off unwanted Hospira operations

Pfizer has sold another Hospira plant, its second in eight weeks, as it continues to whittle down the unwanted operations it picked up in its $15 billion buyout of the sterile drug manufacturer.
- Source: Fiercepharm
- 503
- October 12, 2017
API Company Insight Hospira

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.